Table 2 Univariate assessment of covariates associated with the primary endpoint.

From: High-density Mapping Guided Pulmonary Vein Isolation for Treatment of Atrial Fibrillation - Two-year clinical outcome of a single center experience

 

Univariate analysis

Hazard ratio

p-value

Paroxysmal AF, n (%)*

0.60 [0.35; 1.04]

0.07

Age, years

1.02 [0.99; 1.04]

0.30

Male sex, n (%)*

0.79 [0.46; 1.34]

0.79

CHA2DS2-VASc

1.04 [0.87; 1.24]

0.68

LVEF, %

0.99 [0.97; 1.02]

0.45

LA diameter, mm

1.02 [0.98; 1.06]

0.36

Smoking, n (%)

1.08 [0.56; 2.11]

0.81

Diabetes mellitus, n (%)*

0.75 [0.32; 1.76]

0.51

Stroke, n (%)*

2.08 [1.01; 4.27]

0.06

Hypertension, n (%)*

1.43 [0.74; 2.78]

0.29

Coronary artery disease, n (%)*

1.38 [0.74; 2.57]

0.32

Betablocker, n (%)

1.23 [0.49; 3.09]

0.66

Class I AAD, n (%)

1.26 [0.65; 2.43]

0.50

Class III AAD, n (%)

1.10 [0.53; 2.23]

0.82

  1. The univariate variables with an empirically chosen threshold of a hazard ratio below <0.80 and >1.30 for the primary endpoint of any symptomatic atrial tachycardia (highlighted with an asterisk) were used for the multivariate model. AF, atrial fibrillation; LVEF, left ventricular ejection fraction; LA, left atrial; AAD, antiarrhythmic drugs.
Back to article page